Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups
A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and…











